Up­dat­ed: Af­ter long slog, As­traZeneca fi­nal­ly gets CT­LA-4 drug over fin­ish line

It took years of sort­ing through failed tri­als to find the right dos­ing reg­i­men, but As­traZeneca has fi­nal­ly land­ed an ap­proval for its CT­LA-4 in­hibitor.

Imju­do — bet­ter known as treme­li­mum­ab, or treme — joins Bris­tol My­ers Squibb’s Yer­voy as the on­ly FDA-ap­proved CT­LA-4 drug. The ini­tial OK cov­ers its use in un­re­sectable he­pa­to­cel­lu­lar car­ci­no­ma, the most com­mon type of liv­er can­cer.

As­traZeneca EVP of On­col­o­gy Dave Fredrick­son told End­points News that the cost of the new Imju­do-Imfinzi reg­i­men will be pub­lished in a few days, but that it will be “com­pa­ra­ble” to oth­er ap­proved com­bi­na­tion treat­ments in the liv­er can­cer space.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters